SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luckydog88 who wrote (63052)3/31/2025 1:45:28 PM
From: Olecranon1 Recommendation

Recommended By
jhcimmu

  Read Replies (1) of 63303
 
From a short-to-medium term perspective I suppose this could keep continued pressure on Sarepta’s stock price. But it doesn’t change the fact that Sarepta is and has been a profitable biotech that is not in danger of running past the end of a cash runway.
I consider it a medium-to-long term hold in my own account.
Sarepta has not traded this low since 2022 except for a couple hours on Halloween 2023.
In the current market environment, it’s market fundamentals may be outweighed by trader sentiment so it may not be at a short term bottom and it may not rapidly bounce up. But I’m not sure how much lower it could go.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News